Select region:

Clinical trials located in

Munich

Munich city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Munich, the capital of Bavaria, Germany, is renowned for its rich history, vibrant culture, and architectural marvels. Founded in 1158, it hosts the world-famous Oktoberfest, attracting millions to its beer halls, notably the Hofbräuhaus, established in 1589. The city is a hub of art and science, home to museums like the Deutsches Museum, the world’s largest museum of science and technology. Munich’s skyline is adorned with historical buildings, such as the Neues Rathaus (New Town Hall), and the Frauenkirche, a symbol of the city.

  • CT-EU-00112545

    Evaluating the Safety and Effectiveness of DYNE-101 for Myotonic Dystrophy Type 1 Patients

    This clinical trial is focused on evaluating a new treatment called DYNE-101 for individuals with Myotonic Dystrophy Type 1 (DM1). The main goal is to see how safe and tolerable this treatment is when given through an intravenous (IV) infusion, which means directly into the vein. The study is designed to carefully monitor how participants respond to multiple doses of DYNE-101 over time.

    The trial is structured into four main phases. It starts with a Screening Period that lasts up to 8 weeks to determine eligibility. Following this, there is a multiple-ascending dose (MAD) Placebo-Controlled Period that goes on for 24 weeks, where the safety and effectiveness of different doses of DYNE-101 are compared against a placebo (a treatment with no active drug). This is to ensure that any changes in participants’ health can be accurately attributed to the treatment. After this phase, there is a Treatment Period of another 24 weeks, where all participants receive DYNE-101. The study concludes with a Long-Term Extension (LTE) Period lasting 96 weeks, aimed at understanding the long-term impacts of the treatment.

    One of the key aspects being monitored throughout the study, up to Week 145, is the number of participants who experience any treatment-emergent adverse events (TEAEs), which are any new or worsening health issues that occur during the trial.

    This study represents an important step towards finding a new treatment option for those living with Myotonic Dystrophy Type 1, with a strong focus on safety and the overall well-being of the participants.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • A study of relacorilant in the treatment of hypercortisolism (Cushing’s syndrome) in patients with adrenal adenoma

    This clinical trial focuses on testing the effectiveness and safety of a drug called relacorilant in the treatment of patients with hypercortisolism (Cushing’s syndrome). Hypercortisolism is a condition in which there is too much cortisol in the body, which may occur due to an adenoma or hyperplasia of the adrenal glands that secrete cortisol. This condition can lead to diabetes or impaired glucose tolerance and/or uncontrolled high blood pressure.

    The study is in phase III, which means that the effectiveness and safety of the drug are compared with placebo. This is a double-blind, placebo-controlled study, which means neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo to ensure unbiased results.

    Participants in this study will be randomly assigned to receive relacorilant or placebo for 22 weeks. The main goals of the study are to see how well relakorilant can improve blood sugar levels in patients with diabetes or impaired glucose tolerance, and how it affects blood pressure in people with high blood pressure. Additionally, the study will monitor the safety of relacorilant by recording any adverse events that occur.

    People who complete the study may have the opportunity to continue with a follow-up study, which may provide further information on the long-term effects and benefits of relacorilant.

    AustriaBulgariaGermanyItalyPolandRomaniaSpain
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Examining amivantamab’s effects on advanced colorectal cancer

    This study aims to investigate the effectiveness of a new drug called amivantamab in combating advanced or metastatic colorectal cancer. Amivantamab targets specific factors, namely EGF and MET, crucial for the growth of certain cancers, especially lung cancer, with hope of extending its efficacy to colorectal cancer. Additionally, the study aims to assess the safety of administering the drug alongside standard anti-cancer treatments. The drug will be administered in 28-day cycles, and patients will undergo regular checkups, blood tests, and other necessary assessments. The entire study duration is anticipated to be approximately 4 years and 3 months. Key measurements include monitoring improvements, such as tumor shrinkage, and documenting any encountered side effects in terms of nature, intensity, and the number of affected patients, as per standard procedures in drug trials.

    BelgiumGermanyItalySpain
  • Study on combining radiotherapy & immunotherapy for Biliary Tract Cancer

    This clinical trial investigates a new treatment approach for patients with advanced intrahepatic Biliary Tract Cancer, a type of liver cancer. The study explores the effectiveness of combining Y-90 Selective Internal Radiation Therapy (SIRT) with two immunotherapy drugs, durvalumab and tremelimumab. Participants in this trial will be divided into two groups. One group will receive durvalumab alone, while the other will receive both durvalumab and tremelimumab, following initial SIRT treatment. The trial aims to evaluate the impact of these treatments by comparing clinical outcomes with historical data.

    Germany
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    CzechiaDenmarkFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Study on a new combination therapy for advanced liver cancer

    This study is about trying out a new treatment plan for people with untreated advanced/metastatic hepatocellular carcinoma (HCC). The treatment involves using a combination of three drugs (nivolumab, relatlimab, bevacizumab) compared to a combination of two (nivolumab and bevacizumab). The purpose is to see if adding the third drug can make the treatment more effective, and also to confirm if it’s safe.

    FranceGermanyItalyPolandSpain
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    BelgiumGermanyHungaryPolandUnited Kingdom
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    BelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    AustriaBelgiumFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSlovakiaSloveniaSpainSwedenUnited Kingdom
  • Testing effectiveness and safety of perampanel in pediatric epileptic syndrome

    This research study aims to evaluate the effectiveness and safety of a drug called perampanel in reducing the frequency of seizures in children with childhood epilepsy. The primary objective is to determine whether perampanel can achieve a 50% reduction in the number of seizures experienced by these children. The study involves comparing the seizure frequency during a 28-day treatment period with the baseline seizure frequency before starting the treatment. Additionally, the study incorporates observational and subjective assessments, where both doctors and the children themselves will observe and rate changes in the children’s condition using a 1-7 scoring system.

    BelgiumFranceGermanySpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing Treprostinil Palmitil inhalation powder for pulmonary arterial pressure

    This trial is about a new drug called Treprostinil Palmitil Inhalation Powder (TPIP). TPIP is tested on people who have a condition where the blood pressure in the lungs is too high. This condition is called Pulmonary Arterial Hypertension. The objective of this study is to ascertain the effectiveness and safety of TPIP, and to examine its pharmacokinetics, i.e., how it moves within the body. The trial is set up in such a way that some people will get TPIP, while others receive a placebo. The primary focus is on determining whether TPIP can effectively reduce resistance to blood flow within the lungs, constituting a key aspect of the study’s goals.

    AustriaBelgiumDenmarkGermanyItalySpainUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom

See more clinical trials in other cities in Germany:

.